A top US Food and Drug Administration official says the agency is being “very creative” and “efficient” as it sends its inspectorate back into the field to conduct on-site routine surveillance inspections following a four-month hiatus.
The FDA stopped performing inspections in March at manufacturing facilities in the US and abroad. The agency resumed domestic audits...